國立虎尾科技大學 |

Pharmaceutical Regulatory Environment = Challenges and Opportunities in the Gulf Region /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Pharmaceutical Regulatory Environment/ by Reem K. Al-Essa, Mohammed Al-Rubaie, Stuart Walker, Sam Salek.
其他題名:	Challenges and Opportunities in the Gulf Region /
作者:	Al-Essa, Reem K.
其他作者:	Al-Rubaie, Mohammed.
面頁冊數:	XIII, 236 p. 79 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Public health. -
電子資源:	https://doi.org/10.1007/978-3-319-17590-4
ISBN:	9783319175904

Pharmaceutical Regulatory Environment = Challenges and Opportunities in the Gulf Region /
Al-Essa, Reem K.

Pharmaceutical Regulatory EnvironmentChallenges and Opportunities in the Gulf Region /[electronic resource] :by Reem K. Al-Essa, Mohammed Al-Rubaie, Stuart Walker, Sam Salek. - 1st ed. 2015. - XIII, 236 p. 79 illus. in color.online resource.

1. Overview of Medicines Regulatory Systems in the Gulf Region -- 2. The Regulatory Review Process in the Gulf Region -- 3. Regulatory Review Times in the Gulf Region -- 4. Quality Measures in the Gulf Regulatory Practices -- 5. The Current Status of the Common Technical Document -- 6. The Current Status of Drug Safety and Pharmacovigilance -- 7. The Centralized Regulatory Review in the Gulf Region -- 8. The Gulf States Assessment and Experience With the Centralised Procedure -- 9. The Pharmaceutical Companies Assessment and Experience With the Centralised Procedure -- 10. Proposal For an Improved Centralized Regulatory System -- 11. The Strategic Planning Process of the GCC Regulatory Authorities: Barriers And Solutions -- 12. The Regulatory Dilemma in the Gulf Region: The Way Forward.

The Middle East represents the next growth market for the global biopharmaceutical industry but to date there has been limited information about the regulatory review processes employed in these countries. A thorough examination of the strategies currently being implemented by the Gulf States is considered critical to the future regulatory environment in this region. This book compares national and centralised procedure practices and key performance metrics, including current approval times, review practices and pharmacovigilance standards, in the seven Gulf States. Opportunities for an improved regulatory system are identified, which, if fully implemented, could have a significant impact on patients’ access to new medicines. Pharmaceutical Regulatory Environment: Challenges & Opportunities in the Gulf Region is a must read for those interested in pharmaceutical regulation in the Gulf region.

ISBN: 9783319175904

Standard No.: 10.1007/978-3-319-17590-4doiSubjects--Topical Terms:

560998
Public health.

LC Class. No.: RA1-1270

Dewey Class. No.: 613

Pharmaceutical Regulatory Environment = Challenges and Opportunities in the Gulf Region /
LDR:03117nam a22004095i 4500 001 963373
003 DE-He213
005 20200701143525.0
007 cr nn 008mamaa
008 201211s2015 gw | s |||| 0|eng d
020 $a 9783319175904 $9 978-3-319-17590-4
024 7 $a 10.1007/978-3-319-17590-4 $2 doi
035 $a 978-3-319-17590-4
050 4 $a RA1-1270
072 7 $a MBN $2 bicssc
072 7 $a MED078000 $2 bisacsh
072 7 $a MBN $2 thema
082 0 4 $a 613 $2 23
082 0 4 $a 614 $2 23
100 1 $a Al-Essa, Reem K. $e author. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1258347
245 1 0 $a Pharmaceutical Regulatory Environment $h [electronic resource] : $b Challenges and Opportunities in the Gulf Region / $c by Reem K. Al-Essa, Mohammed Al-Rubaie, Stuart Walker, Sam Salek.
250 $a 1st ed. 2015.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Adis, $c 2015.
300 $a XIII, 236 p. 79 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a 1. Overview of Medicines Regulatory Systems in the Gulf Region -- 2. The Regulatory Review Process in the Gulf Region -- 3. Regulatory Review Times in the Gulf Region -- 4. Quality Measures in the Gulf Regulatory Practices -- 5. The Current Status of the Common Technical Document -- 6. The Current Status of Drug Safety and Pharmacovigilance -- 7. The Centralized Regulatory Review in the Gulf Region -- 8. The Gulf States Assessment and Experience With the Centralised Procedure -- 9. The Pharmaceutical Companies Assessment and Experience With the Centralised Procedure -- 10. Proposal For an Improved Centralized Regulatory System -- 11. The Strategic Planning Process of the GCC Regulatory Authorities: Barriers And Solutions -- 12. The Regulatory Dilemma in the Gulf Region: The Way Forward.
520 $a The Middle East represents the next growth market for the global biopharmaceutical industry but to date there has been limited information about the regulatory review processes employed in these countries. A thorough examination of the strategies currently being implemented by the Gulf States is considered critical to the future regulatory environment in this region. This book compares national and centralised procedure practices and key performance metrics, including current approval times, review practices and pharmacovigilance standards, in the seven Gulf States. Opportunities for an improved regulatory system are identified, which, if fully implemented, could have a significant impact on patients’ access to new medicines. Pharmaceutical Regulatory Environment: Challenges & Opportunities in the Gulf Region is a must read for those interested in pharmaceutical regulation in the Gulf region.
650 0 $a Public health. $3 560998
650 0 $a Pharmacotherapy. $3 973587
650 1 4 $a Public Health. $3 592982
700 1 $a Al-Rubaie, Mohammed. $e author. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1258348
700 1 $a Walker, Stuart. $e author. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1258349
700 1 $a Salek, Sam. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1208851
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319175911
776 0 8 $i Printed edition: $z 9783319175898
776 0 8 $i Printed edition: $z 9783319360102
856 4 0 $u https://doi.org/10.1007/978-3-319-17590-4
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)